The Impact of Left Stellate Ganglion Block on Systemic Inflammation and Neuromodulation in CABG Surgery.
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-85
SponsorOMAR ABDELAZIZ ABOELFADL
About this trial
((82)) patients scheduled to undergo elective CABG by the same surgical team will be allocated randomly by computer-generated random numbers into two equal groups (n= 41).
Study groups:
Group S (Stellate Ganglion Block Group):
Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome.
Group C (Control Group):
Patients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S.
Eligibility criteria
Qualifiers
All elderly (≥65 years) patients of both genders, as according to the World Health Organization, the chronologic age of 65 years was accepted by most developed countries in the world as a definition of "elderly" or older person. Patients scheduled for elective cardiac surgery under general anesthesia.14
American Society of Anesthesiologists (ASA) physical status class II or III.
Patients will be stratified according to their baseline surgical risk utilizing the EuroSCORE II tool >4%15.
American Society of Anesthesiologists (ASA) physical status class II or III.
Disqualifiers
Pre-existing dementia or significant cognitive impairment.
History of stroke or cerebrovascular disease.
Contraindications to SGB (e.g., coagulopathy, local infection, or anatomical abnormalities).
Preoperative use of antipsychotics or antidepressants.
Trial design
Treatments tested in this trial
- Stellate Ganglion Block
Treatment groups
81 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
OMAR ABDELAZIZ ABOELFADL
Lead sponsor
Assiut University
Sponsor institution
Source ClinicalTrials.gov